A G Ellis1, P T Zeglinski2, D J Brown3, A G Frauman1, M Millard4, J B Furness5. 1. 1] Clinical Pharmacology and Therapeutics, Austin Health, Heidelberg, Victoria, Australia [2] Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia. 2. Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia. 3. 1] Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia [2] Spinal Research Institute, Royal Talbot Rehabilitation Centre, Victoria, Australia. 4. Spinal Research Institute, Royal Talbot Rehabilitation Centre, Victoria, Australia. 5. 1] Spinal Research Institute, Royal Talbot Rehabilitation Centre, Victoria, Australia [2] Department of Anatomy and Neuroscience, University of Melbourne, Parkville, Victoria, Australia.
Abstract
STUDY DESIGN: Single centre, single ascending dose study. OBJECTIVES: To compare the pharmacokinetics and assess the safety of capromorelin, a compound that has potential to treat constipation following spinal cord injury (SCI), in groups of able-bodied and SCI volunteers. SETTING:Local population from Victoria, Australia. METHODS: Following initial screening and baseline blood collections, participants received ascending oral doses (20, 50 and then 100 mg at least 1-week apart) of capromorelin after pre-dose blood collection, followed by blood collections over the following 12 h for pharmacokinetic analysis and 1-week and 4-week follow-up blood collections for safety evaluations. Blood pressure and heart rate were monitored. RESULTS: No serious adverse events were recorded following any dose in either the able-bodied group or the SCI group. There were no abnormal blood pressure or heart rate changes. Minor adverse events resolved quickly without the need for treatment. Pharmacokinetic behaviour was broadly similar between groups, with both exhibiting dose-dependent increases in Cmax and AUC0-∞. The SCI participants showed greater variance in pharmacokinetic parameters and had a slightly delayed Tmax and half-life. CONCLUSION: Capromorelin at the doses tested was safe and well tolerated in both SCI and able-bodied participants and also showed similar pharmacokinetics with dose-dependent increases in concentration and drug exposure.
RCT Entities:
STUDY DESIGN: Single centre, single ascending dose study. OBJECTIVES: To compare the pharmacokinetics and assess the safety of capromorelin, a compound that has potential to treat constipation following spinal cord injury (SCI), in groups of able-bodied and SCI volunteers. SETTING: Local population from Victoria, Australia. METHODS: Following initial screening and baseline blood collections, participants received ascending oral doses (20, 50 and then 100 mg at least 1-week apart) of capromorelin after pre-dose blood collection, followed by blood collections over the following 12 h for pharmacokinetic analysis and 1-week and 4-week follow-up blood collections for safety evaluations. Blood pressure and heart rate were monitored. RESULTS: No serious adverse events were recorded following any dose in either the able-bodied group or the SCI group. There were no abnormal blood pressure or heart rate changes. Minor adverse events resolved quickly without the need for treatment. Pharmacokinetic behaviour was broadly similar between groups, with both exhibiting dose-dependent increases in Cmax and AUC0-∞. The SCI participants showed greater variance in pharmacokinetic parameters and had a slightly delayed Tmax and half-life. CONCLUSION:Capromorelin at the doses tested was safe and well tolerated in both SCI and able-bodied participants and also showed similar pharmacokinetics with dose-dependent increases in concentration and drug exposure.
Authors: Yasutake Shimizu; Ed C Chang; Anthony D Shafton; Dorota M Ferens; Gareth J Sanger; Jason Witherington; John B Furness Journal: J Physiol Date: 2006-07-27 Impact factor: 5.182
Authors: K Krogh; M Bach Jensen; P Gandrup; S Laurberg; J Nilsson; R Kerstens; M De Pauw Journal: Scand J Gastroenterol Date: 2002-04 Impact factor: 2.423
Authors: Mark A Korsten; Alan S Rosman; Anthony Ng; Erdal Cavusoglu; Ann M Spungen; Miroslav Radulovic; Jill Wecht; William A Bauman Journal: Am J Gastroenterol Date: 2005-07 Impact factor: 10.864
Authors: Heidi K White; Charles D Petrie; William Landschulz; David MacLean; Ann Taylor; Kenneth Lyles; Jeanne Y Wei; Andrew R Hoffman; Roberto Salvatori; Mark P Ettinger; Miriam C Morey; Marc R Blackman; George R Merriam Journal: J Clin Endocrinol Metab Date: 2009-01-27 Impact factor: 5.958
Authors: Alan S Rosman; Geeta Chaparala; Amit Monga; Ann M Spungen; William A Bauman; Mark A Korsten Journal: Dig Dis Sci Date: 2008-03-13 Impact factor: 3.199
Authors: Ruslan V Pustovit; Brid Callaghan; Mitchell T Ringuet; Nicole F Kerr; Billie Hunne; Ian M Smyth; Claudio Pietra; John B Furness Journal: Physiol Rep Date: 2017-08
Authors: Gianfabio Giorgioni; Fabio Del Bello; Wilma Quaglia; Luca Botticelli; Carlo Cifani; E Micioni Di Bonaventura; M V Micioni Di Bonaventura; Alessandro Piergentili Journal: J Med Chem Date: 2022-02-14 Impact factor: 7.446